TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14585939

Group type: EXPERIMENTAL
Intervention: ximelagatran (24 mg, taken twice daily for 18 months)
Number of subjects: 1233

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1233
Study: 10972907

Group type: EXPERIMENTAL
Intervention: G‐CSF (300 microg filgrastim) given three times weekly for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9526580

Group type: EXPERIMENTAL
Intervention: Filgrastim (5 mg/kg) following PBPC infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard support care only
Number of subjects: 26
Study: 8317948

Group type: EXPERIMENTAL
Intervention: 2‐deoxyglucose (2DG) 50 mg/kg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3555126

Group type: EXPERIMENTAL
Intervention: Pimozide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31692226

Group type: EXPERIMENTAL
Intervention: Exenatide (EXE) once weekly + dapagliflozin (DAPA) once daily
Number of subjects: 695

Group type: COMPARATOR
Intervention: Exenatide (EXE) once weekly + placebo (PLB)
Number of subjects: 695

Group type: COMPARATOR
Intervention: Dapagliflozin (DAPA) + placebo (PLB)
Number of subjects: 695
Study: 28550417

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) in addition to standard functional restoration program
Number of subjects: 728

Group type: COMPARATOR
Intervention: Standard functional restoration program (control)
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) adherence
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Unemployed claimants
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Employed claimants
Number of subjects: 728
Study: 26535593

Group type: EXPERIMENTAL
Intervention: Febuxostat 40-80 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Allopurinol 100-300 mg daily
Number of subjects: 0
Study: 25490971

Group type: EXPERIMENTAL
Intervention: Training of LHSs to build knowledge and skills, clinical mentorship, and written feedback to LHWs.
Number of subjects: 170

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 170
Study: 22749443

Group type: EXPERIMENTAL
Intervention: PRISM intervention (Program of Resources, Information and Support for Mothers)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Document analysis
Number of subjects: 0
Study: 20378235

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention (COMPASS) including a newly designed ward observation chart, a track and trigger system, and an associated education program
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Multi-faceted intervention (COMPASS)
Number of subjects: 1157
Study: 18206734

Group type: EXPERIMENTAL
Intervention: 1997 ADA IFG definition (fasting plasma glucose 110 to 125 mg/dl)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: 2003 ADA IFG definition (fasting plasma glucose 100 to 125 mg/dl)
Number of subjects: 423

Group type: COMPARATOR
Intervention: Diabetes (as a comparison group)
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: 1997 ADA IFG definition
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: 2003 ADA IFG definition
Number of subjects: 423
Study: 15870317

Group type: EXPERIMENTAL
Intervention: Standard formula supplemented with galacto‐ and fructo‐oligosaccharides (OSF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 0
Study: 12087953

Group type: EXPERIMENTAL
Intervention: Fluoroquinolone prophylaxis
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no fluoroquinolone prophylaxis)
Number of subjects: 70
Study: 14518329

Group type: EXPERIMENTAL
Intervention: J pouch anastomosis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Coloanal reconstruction
Number of subjects: 40
Study: 7986706

Group type: EXPERIMENTAL
Intervention: Interleukin‐3 (IL‐3) at 10 micrograms/kg/d
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Interleukin‐3 (IL‐3) at 15 micrograms/kg/d
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (ICE chemotherapy without IL‐3)
Number of subjects: 27
Study: 2525397

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with medroxyprogesterone acetate at high dosage (HD‐MPA; 500 mg IM per day times 28 or 500 mg i.m. 5 days a week for 5 weeks then 500 mg i.m. twice weekly for the 5 following months
Number of subjects: 240

Group type: COMPARATOR
Intervention: No hormone therapy
Number of subjects: 240
Study: 4883651

Group type: EXPERIMENTAL
Intervention: Oral contraceptive with low oestrogen/progestogen content
Number of subjects: 20

Group type: COMPARATOR
Intervention: Identical dummy tablets (control)
Number of subjects: 20
Study: 107450

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg
Number of subjects: 1080

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 1080
Study: 31172823

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training protocol with incremental loading (50%, 60%, and 70% of MIP) for 12 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group performed with load 15% of MIP
Number of subjects: 17
Study: 31727410

Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 28752693

Group type: EXPERIMENTAL
Intervention: Human bone mineral allograft (freeze-dried bone allograft, FDBA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Biphasic calcium phosphate (BCP) alloplastic bone substitute
Number of subjects: 13
Study: 26382217

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 177
Study: 23323877

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 21290116

Group type: EXPERIMENTAL
Intervention: Hamstring autograft (group I)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Achilles allograft (group II)
Number of subjects: 106
Study: 19556318

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.5 mg/m2 24 h (arm A)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Trabectedin 1.3 mg/m2 3 h (arm B)
Number of subjects: 107
Study: 17373190

Group type: EXPERIMENTAL
Intervention: 5% oleic acid emulsion before phototherapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: Phototherapy without emulsion
Number of subjects: 44
Study: 14718678

Group type: EXPERIMENTAL
Intervention: Levodopa combined with COMT inhibitor entacapone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levodopa combined with entacapone
Number of subjects: 0
Study: 11239866

Group type: EXPERIMENTAL
Intervention: unoprostone isopropyl 0.12%
Number of subjects: 41

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study: 9885092

Group type: EXPERIMENTAL
Intervention: Psychological intervention consisting of 35 weekly, 2 h sessions of supportive plus cognitive behavioral therapy; n = 30
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group received only a home study cognitive behavioral package; n = 36
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Self-reported exercise
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Intervention subjects who attended outside support groups
Number of subjects: 66
Study: 7987430

Group type: EXPERIMENTAL
Intervention: Vocal function exercises
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo exercise program
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 2691402

Group type: EXPERIMENTAL
Intervention: Test toothpaste with 550 ppm fluoride
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control toothpaste with 1055 ppm fluoride
Number of subjects: 3000
Study: 30864473

Group type: EXPERIMENTAL
Intervention: Discharge analgesia prescribing compliance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Paracetamol compliance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Celecoxib compliance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxycodone immediate release (IR) compliance
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxycodone IR quantity compliance
Number of subjects: 100
Study: 28236467

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy screening
Number of subjects: 170034

Group type: COMPARATOR
Intervention: Control group (not contacted)
Number of subjects: 170034
Study: 25580979

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Exercise (MICE)
Number of subjects: 81
Study: 23972891

Group type: EXPERIMENTAL
Intervention: Cartridge-insertion technique
Number of subjects: 144

Group type: COMPARATOR
Intervention: Wound-assisted technique
Number of subjects: 144
Study: 21653795

Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed formula
Number of subjects: 2159

Group type: COMPARATOR
Intervention: Standard cow milk-based weaning formulas
Number of subjects: 2159
Study: 19661695

Group type: EXPERIMENTAL
Intervention: Medium- and long-chain triacylglycerols (MLCT) oil
Number of subjects: 2

Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (LCT) oil
Number of subjects: 2
Study: 17381566

Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.5% (20 ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 120
Study: 14688594

Group type: COMPARATOR
Intervention: Captopril renography
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exercise renography
Number of subjects: 29

Group type: COMPARATOR
Intervention: Captopril renography (patient basis)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exercise renography (patient basis)
Number of subjects: 29
Study: 12363117

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (median dose 150 mg, range 50-300 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 42
Study: 9768652

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 15
Study: 7979646

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 0
Study: 2589761

Group type: EXPERIMENTAL
Intervention: Prototype endotracheal tube (ETT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard endotracheal tube (ETT)
Number of subjects: 0
Study: 1103574

Group type: EXPERIMENTAL
Intervention: Maprotiline (Ludiomil)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Amitriptyline (Elavil)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Maprotiline and Amitriptyline (both drugs)
Number of subjects: 67
Study: 30729363

Group type: EXPERIMENTAL
Intervention: Full Program condition (access to all services available from the Relief Nursery)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Respite Care condition (access only to respite care and referrals to services provided by other community agencies)
Number of subjects: 0
Study: 30811280

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (NIVO3+IPI1)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3)
Number of subjects: 360
Study: 27007714

Group type: EXPERIMENTAL
Intervention: Engage in Education‐London (EiE‐L) intervention, delivered over 12 weeks
Number of subjects: 644

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 644
Study: 25622639

Group type: EXPERIMENTAL
Intervention: MiQuit intervention (12-week tailored, supportive, interactive text message self-help cessation support)
Number of subjects: 400

Group type: COMPARATOR
Intervention: NHS leaflet aimed at helping them to stop smoking
Number of subjects: 400
Study: 23695652

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy (OMT) including lifestyle intervention and intensive secondary prevention with proven pharmacotherapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Myocardial revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COURAGE and FAME 2 trials
Number of subjects: 0
Study: 21105835

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 96

Group type: COMPARATOR
Intervention: Oral contraceptive pills (OCPs)
Number of subjects: 96
Study: 19478339

Group type: EXPERIMENTAL
Intervention: CHO+ProH beverage (6% carbohydrate + 1.8% protein hydrolysate)
Number of subjects: 13

Group type: COMPARATOR
Intervention: CHO beverage (6% carbohydrate)
Number of subjects: 13
Study: 16636139

Group type: EXPERIMENTAL
Intervention: Quantile regression model with random effects using asymmetric Laplace distribution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mean regression with random effects
Number of subjects: 0
Study: 14583439

Group type: EXPERIMENTAL
Intervention: Protocol 2 (6 h of mild hyperglycemia, approximately 7 mmol/l)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Protocol 3 (6 h of euglycemia)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Protocol 1 (glucose varied to mimic a postprandial pattern, peak glucose approximately 11.1 mmol/l)
Number of subjects: 25
Study: 11804426

Group type: EXPERIMENTAL
Intervention: P1 medium supplemented with 20% SSS (Group 3)
Number of subjects: 956

Group type: COMPARATOR
Intervention: P1 medium supplemented with 10% SSS (Group 2)
Number of subjects: 956

Group type: COMPARATOR
Intervention: IVF medium (Group 1)
Number of subjects: 956
Study: 9415507

Group type: EXPERIMENTAL
Intervention: Physician pain scale (assessed by visual analogue scale)
Number of subjects: 91

Group type: COMPARATOR
Intervention: No analgesic treatment
Number of subjects: 91
Study: 8395380

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMW heparin) administered subcutaneously once daily
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 241
Study: 3706840

Group type: EXPERIMENTAL
Intervention: General anaesthesia with sodium thiopentone, fentanyl, enflurane, and vecuronium
Number of subjects: 70

Group type: COMPARATOR
Intervention: Spinal anaesthesia with 3 ml 0.5% bupivacaine in isobaric solution
Number of subjects: 70
Study: 31846067

Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IA)
Number of subjects: 140
Study: 30307692

Group type: EXPERIMENTAL
Intervention: Buzzy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Buzzy and ShotBlocker
Number of subjects: 60
Study: 26846664

Group type: EXPERIMENTAL
Intervention: Videos of chewing people
Number of subjects: 0

Group type: COMPARATOR
Intervention: Videos of nature and buildings (Control)
Number of subjects: 0
Study: 25153050

Group type: EXPERIMENTAL
Intervention: Kiosk
Number of subjects: 317

Group type: COMPARATOR
Intervention: IPS
Number of subjects: 317
Study: 21919060

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sertraline responders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nortriptyline responders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline non-responders
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nortriptyline non-responders
Number of subjects: 0
Study: 20206786

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (3, 9, and 15 mg/d; 6, 9, and 12 mg/d; 6 and 12 mg/d)
Number of subjects: 1306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1306
Study: 17012146

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH) at an end‐tidal partial pressure of O(2) of 55 mmHg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 10
Study: 16266859

Group type: EXPERIMENTAL
Intervention: 300 mg n-3 PUFA + 700 mg canola oil
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1 g canola oil (control)
Number of subjects: 21
Study: 12019663

Group type: EXPERIMENTAL
Intervention: Paroxetine (20-40 mg daily)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-60 mg daily)
Number of subjects: 242
Study: 10466664

Group type: EXPERIMENTAL
Intervention: Community-wide oral azithromycin treatment (three doses with intervals of 1 week)
Number of subjects: 1511

Group type: COMPARATOR
Intervention: 1% topical tetracycline (once daily for 6 weeks)
Number of subjects: 1511
Study: 7604667

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positive patients
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Helicobacter pylori status
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Colonization rate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Eradication rate
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Chronic gastritis
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Initial endoscopy results
Number of subjects: 200
Study: 1731005

Group type: EXPERIMENTAL
Intervention: High PEEP (12 to 14 cm H2O)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Low PEEP (3 to 5 cm H2O)
Number of subjects: 74
Study: 3918426

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombolytic therapy with streptokinase (STK)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Corticosteroids and intracoronary and intravenous nitroglycerin (NTG group)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional means (control group)
Number of subjects: 64
Study: 31710269

Group type: EXPERIMENTAL
Intervention: SBIRT mobile app
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (no app)
Number of subjects: 101
Study: 31554937

Group type: EXPERIMENTAL
Intervention: Esaxerenone monotherapy
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Esaxerenone with CCB
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Esaxerenone with RAS inhibitor
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Esaxerenone
Number of subjects: 368
Study: 29797621

Group type: EXPERIMENTAL
Intervention: Tobacco Status Project (TSP) Facebook intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: Referral to the National Cancer Institute Smokefree.gov website (Control)
Number of subjects: 500
Study: 25533646

Group type: EXPERIMENTAL
Intervention: Mesalazine, 800 mg, three times daily for 12 weeks
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo, three times daily for 12 weeks
Number of subjects: 185
Study: 25697457

Group type: EXPERIMENTAL
Intervention: 532-nm subthreshold laser grid photocoagulation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Threshold laser grid photocoagulation
Number of subjects: 23
Study: 23566712

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4
Number of subjects: 200

Group type: COMPARATOR
Intervention: Balanced electrolyte solution
Number of subjects: 200
Study: 19853518

Group type: EXPERIMENTAL
Intervention: Active TENS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 24
Study: 19114201

Group type: EXPERIMENTAL
Intervention: Single-dose cefazolin (2 g)
Number of subjects: 838

Group type: COMPARATOR
Intervention: 24-hour treatment of cefazolin (2-g initial dose, followed by 1 g every 8 hours)
Number of subjects: 838
Study: 16669901

Group type: EXPERIMENTAL
Intervention: Intensive referral to 12-Step self-help groups
Number of subjects: 345

Group type: COMPARATOR
Intervention: Standard referral
Number of subjects: 345
Study: 12828083

Group type: EXPERIMENTAL
Intervention: Twice-a-day interferon-beta (3 MU) for 3 weeks followed by once-a-day interferon-beta (6 MU) for 5 weeks (group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Once-a-day interferon-beta (6 MU) for 8 weeks (group B)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Twice-a-day interferon-beta (group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Once-a-day interferon-beta (group B)
Number of subjects: 49
Study: 11074884

Group type: EXPERIMENTAL
Intervention: 131I-lipiodol (1110-MBq dose) administered into the hepatic artery
Number of subjects: 28
Study: 7700739

Group type: EXPERIMENTAL
Intervention: End-stage renal disease (ESRD)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Preterminal chronic renal failure
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (idiopathic short stature)
Number of subjects: 35
Study: 2695130

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 381

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 381
Study: 79319

Group type: EXPERIMENTAL
Intervention: 2-month initial intensive phase of streptomycin, isoniazid, rifampin, and pyrazinamide followed by daily thiacetazone and isoniazid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1-month initial intensive phase of streptomycin, isoniazid, rifampin, and pyrazinamide followed by twice-weekly administration of streptomycin, isoniazid, and pyrazinamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regimen omitting pyrazinamide from the initial intensive 2-month phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total duration of chemotherapy increased from 6 months to 8 months
Number of subjects: 0
Study: 30362982

Group type: EXPERIMENTAL
Intervention: Video Games (VG)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Cartoon Movies (CM)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Parental Interaction (PI)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 180
Study: 29097166

Group type: EXPERIMENTAL
Intervention: Active product (125 mL once-a-day drink containing Fortasyn Connect)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Active product
Number of subjects: 311
Study: 25399241

Group type: EXPERIMENTAL
Intervention: Weekly acupuncture treatment (n = 118)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Oral tolterodine tartrate 2 mg twice daily (n = 122)
Number of subjects: 240
Study: 24073528

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating (O-R) power toothbrush
Number of subjects: 462
Study: 21680210

Group type: EXPERIMENTAL
Intervention: Oral morphine 0.25 mg/kg body weight
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18375792

Group type: EXPERIMENTAL
Intervention: Rituximab treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control individuals
Number of subjects: 0